Trials
2 active
2 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Main trialPhase 2
- “The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)”In the company’s words, NCT06993610 on ClinicalTrials.gov
- Other names
- ZB-106
Other drugs for Hidradenitis Suppurativa (HS)
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
Coming up1
- May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 18 Sep 2026 | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | |
| Phase 2Active, not recruiting | May 2027 | Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026